<DOC>
	<DOCNO>NCT00680745</DOCNO>
	<brief_summary>This study carry see dapagliflozin addition glimepiride ( sulphonylurea ) effective safe treat patient type 2 diabetes compare glimepiride alone .</brief_summary>
	<brief_title>Efficacy Safety Dapagliflozin Combination With Glimepiride ( Sulphonylurea ) Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes Treatment stable sulphonylurea monotherapy dose least half maximal recommend dose minimum 8 week prior study Inadequate glycaemic control , define A1C ≥ 7.0 % ≤ 10 % Type 1 Diabetes Hepatic ( liver ) impairment Renal ( kidney ) failure dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>sulphonylurea</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>